Blood cytokines as potential predictors of therapy effectiveness in patients with moderate to severe psoriasis treated with the IL-12/IL-23 inhibitor ustekinumab
Background. Despite the proven efficacy and safety of biologics in the treatment of psoriasis (Ps), a number of patients experience heterogeneity in response to therapy in both the short-term and long-term perspectives. Aims. To identify correlations between the blood cytokine levels, clinical se...
Saved in:
| Main Authors: | Arfenya E. Karamova, Anastasiia A. Vorontsova, Alexandr А. Nikonorov, Evgenia R. Nikonorova, Аlexey A. Kubanov |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
State Scientific Center of Dermatovenereology and Cosmetology
2025-03-01
|
| Series: | Vestnik Dermatologii i Venerologii |
| Subjects: | |
| Online Access: | https://vestnikdv.ru/jour/article/viewFile/16814/pdf_1 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
RESULTS OF USTEKINUMAB TREATMENT IN PATIENTS WITH PSORIATIC ARTHRITIS IN THE RUSSIAN FEDERATION ACCORDING TO THE DATA OF PSUMMIT 1 AND PSUMMIT 2
by: Yu. L. Korsakova, et al.
Published: (2015-04-01) -
Guselkumab Retention, Effectiveness, and Safety in Psoriasis: A 260-Week Real-World Multicenter Retrospective Study Exploring the Role of Concomitant PsA–IL PSO (Italian Landscape Psoriasis)
by: Mario Valenti, et al.
Published: (2025-07-01) -
IgA Vasculitis Induced by Ustekinumab During Treatment for Crohn’s Disease: A Case Report
by: Yu Okada, et al.
Published: (2025-08-01) -
Immunopathogenetic mechanisms of action of ustekinumab, a new drug for the treatment of psoriatic arthritis and psoriasis
by: T. V. Korotaeva, et al.
Published: (2015-06-01) -
IL-17A, IL-17F and IL-23 in patients with rheumatoid arthritis
by: Natalia A. Lapkina, et al.
Published: (2024-09-01)